Vertex Pharmaceuticals Inc (VRTX) stock news · P/E 30, rev $3.33B
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
This VRTX news page leads with what Vertex Pharmaceuticals Inc filed — not a scraped headline mill.
No cached 8-K sentence for VRTX yet. We will not pad this page with generic market recap.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the VRTX stock page; for the tape open the quote page.
VRTX cached headlines
- 2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 — Yahoo Finance
- How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks? — Yahoo Finance
- Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks — Yahoo Finance
- Goldman Sachs refreshes conviction lists on both sides of the Atlantic — Yahoo Finance
- Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds — Yahoo Finance
- Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform — Yahoo Finance
- Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team — Yahoo Finance
- OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel — Yahoo Finance
- 1 S&P 500 Stock with Exciting Potential and 2 We Ignore — Yahoo Finance
- Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? — Yahoo Finance
- Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock — Yahoo Finance
- Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead — Yahoo Finance
Not investment advice.